Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

ABUS Arbutus Biopharma Corporation Common Stock
$4.51 -3.40% -0.16
Notify me if price changes either direction
Interactive Brokers Logotype

Buy ABUS stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 871.2M
Enterprise value 782.1M
Trailing PE -11.947368320666
Forward PE -27.10018
PEG Ratio 0.19912280534443
Enterprise to EBITDA -25.502
Enterprise to revenue 53.549
Price to book MRQ 11.240695
Price to sales TTM 59.64863

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 14.6M
EBITDA -30670000
Diluted EPS TTM -0.23
Total Cash (MRQ) 93.7M
Current ratio (MRQ) 18.797
Operating Cash Flow (TTM) -45272000

ABUS trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent ABUS News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.